Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial
Research article
[키워드] 1:1
95% CI
ACE2
adaptive
added
Admission
adverse event
age
Analysis
angiotensin
Anti-inflammatory effects
ARB
ARBs
blocker
Buenos Aire
Buenos Aires
C-reactive protein (CRP
Community
Completed
Composite
Control
COVID-19
criteria
CRP
CRP level
Day
death
discharge
enrolled
enzyme
expressed
finding
funding
groups
hospital
Hospitalized
hospitalized patient
ICU
inhibitor
intensive care
interim analysis
Kaplan-Meier analysis
Lung inflammation
mechanical ventilation
median
morbidity and mortality
multicenter
Open-label
outcome
parallel-group
participant
Patient
plasma
Pragmatic
randomization
Randomized
randomized clinical trial
receptor
recruitment
reduce
reduction in
reported
Safe
secondary
Serum level
standard care
standard care group
symptom onset
telmisartan
therapeutic
to define
treat
Treatment
treatment arm
Trial
Two-arm
was reduced
[DOI] 10.1016/j.eclinm.2021.100962 [Article Type] Research article
[DOI] 10.1016/j.eclinm.2021.100962 [Article Type] Research article